Haloperidol plasma ‘threshold’ levels for relapse prevention in schizophrenia: a study with haloperidol decanoate-Reference-Cited by-同舟云学术

Haloperidol plasma ‘threshold’ levels for relapse prevention in schizophrenia: a study with haloperidol decanoate

Published:1995-01 Issue: Volume:5 Page:55-58
ISSN:0924-977X
Container-title:European Neuropsychopharmacology
language:en
Short-container-title:European Neuropsychopharmacology

Author:

Altamura A.C,Tacchinib G.L,Maes M

Publisher

Elsevier BV

Subject

Pharmacology (medical),Biological Psychiatry,Psychiatry and Mental health,Neurology (clinical),Neurology,Pharmacology

Reference14 articles.

1. Haloperidol determination in serum and cerebrospinal fluid using gas-liquid gaschromatograph with nitrogen /phosphorus detection: application to pharmacokinetic studies;Abernethy;J. Chromatogr.,1984

2. Pharmacokinetic issues in the management of schizophrenia;Altamura,1989

3. A multidimensional (pharmacokinetic and clinical-biological) approach to neuroleptic response in schizophrenia (with particular reference to drug resistance);Altamura;Schizophr. Res.,1992

4. Haloperidol decanoate in chronic schizophrenia: a follow-up study of 12 months with plasma levels. Prog. Neuropsychopharmacol;Altamura;Biol. Psychiatry,1990

5. Low-dose depot medication in schizophrenia;Burnett;Schizophr. Bull.,1993

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A review on schizophrenia and relapse-a quest for user-friendly psychopharmacotherapy;Human Psychopharmacology: Clinical and Experimental;2014-07-23

2. A comparison of continuous subcutaneous paliperidone infusion and repeated subcutaneous injection of risperidone free-base in rats;European Psychiatry;2010-03

3. Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable;European Neuropsychopharmacology;2006-05

4. Establishing a dose–response relationship for haloperidol decanoate;Psychiatric Bulletin;2005-03

5. Intramuscular Preparations of Antipsychotics;Drugs;2003